Get the Stockscreener App
2.08
3.48%
-0.075
Radiopharm Theranostics Ltd Adr stock is traded at $2.08, with a volume of 7,908.
It is down -3.48% in the last 24 hours and down -28.77% over the past month.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
See More
Previous Close:
$2.155
Open:
$2.05
24h Volume:
7,908
Relative Volume:
0.12
Market Cap:
$16.40M
Revenue:
$2.34M
Net Income/Loss:
$-30.37M
P/E Ratio:
-0.7069
EPS:
-2.9424
Net Cash Flow:
$-23.42M
1W Performance:
-13.69%
1M Performance:
-28.77%
6M Performance:
-56.85%
1Y Performance:
-62.86%
1-Day Range:
$2.05
$2.145
1-Week Range:
$2.05
$2.4421
52-Week Range:
$2.0437
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Name
Radiopharm Theranostics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare RADX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
2.08 | 18.05M | 2.34M | -30.37M | -23.42M | -2.9424 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Stock (RADX) Latest News
Radiopharm Theranostics rebuilds its balance sheet as cancer pipeline delivers early trial wins - Kalkine
Radiopharm Theranostics (RADX) seeks shareholder approval for placements, SPP and new warrants - Stock Titan
Radiopharm Theranostics Applies to Quote 408.8 Million Shares from Tranche 1 Australian Placement - Kalkine
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Stock Analysis - vinanet.vn
Radiopharm Theranostics Reports Business Update - Sahm
Radiopharm stock tumbles 21% on dilutive capital raise By Investing.com - Investing.com Nigeria
Radiopharm Theranostics Raises A$12.5 Million in Institutional Capital as RAD101 Phase 3 Trial Nears Commencement - Kalkine
Radiopharm stock tumbles 21% on dilutive capital raise - Investing.com
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials - smallcaps.com.au
Radiopharm Theranostics (RADX) Holds Steady Near Support Amid Light TradingOBV Breakout - Vinanet
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Radiopharm Theranostics Limited Financial Disclosures & SEC Filings - TradingView
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright - Investing.com
RADXRadiopharm Theranostics Ltd ADR Stock Price and Quote - Finviz
Radiopharm Theranostics (RADX) Institutional Ownership 2026 - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference - Yahoo Finance
RAD: Multiple first-in-class radiopharmaceuticals advance in parallel, with key data readouts expected soon - TradingView
RAD: Multiple phase I trials and an imaging agent drive near-term catalysts and long-term value - TradingView
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs - Yahoo Finance
Unusual VolumeStock ScreenerNews - Finviz
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Radiopharm Theranostics (NASDAQ: RADX) faces 1.29-quarter cash runway - Stock Titan
Radiopharm Theranostics Reports Business Update - GlobeNewswire Inc.
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 - Yahoo Finance
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
Radiopharm Theranostics LimitedSponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest - MarketBeat
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial - Yahoo Finance
Radiopharm Theranostics Taps Siemens for U.S. Supply of Fast-Tracked Brain Metastases Imaging Agent RAD101 - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Radiopharm Theranostics Doses First Patient in Phase 1 RAD 402 Prostate Cancer Trial - TipRanks
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study - Yahoo Finance
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Ocugen (OCGN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Radiopharm Theranostics Ltd Adr Stock (RADX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):